Cargando…

Parecoxib relieves pain and has an opioid-sparing effect following major gastrointestinal surgery

PURPOSE: Parecoxib provides analgesia following a variety of surgeries, including minor gastrointestinal procedures. To our knowledge, there is no data on parecoxib following major gastrointestinal surgery. This study assessed the efficacy and opioid-sparing effects of parecoxib following major gast...

Descripción completa

Detalles Bibliográficos
Autores principales: Essex, Margaret Noyes, Xu, Hao, Parsons, Bruce, Xie, Li, Li, Chunming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627739/
https://www.ncbi.nlm.nih.gov/pubmed/29026330
http://dx.doi.org/10.2147/IJGM.S143837
_version_ 1783268760309727232
author Essex, Margaret Noyes
Xu, Hao
Parsons, Bruce
Xie, Li
Li, Chunming
author_facet Essex, Margaret Noyes
Xu, Hao
Parsons, Bruce
Xie, Li
Li, Chunming
author_sort Essex, Margaret Noyes
collection PubMed
description PURPOSE: Parecoxib provides analgesia following a variety of surgeries, including minor gastrointestinal procedures. To our knowledge, there is no data on parecoxib following major gastrointestinal surgery. This study assessed the efficacy and opioid-sparing effects of parecoxib following major gastrointestinal surgeries. PATIENTS AND METHODS: Patients in this analysis were a subset from a large, randomized, double-blind, placebo-controlled trial of parecoxib following noncardiac surgeries and consisted of those undergoing a variety of major gastrointestinal surgeries via laparotomy. Pain, pain interference with function, supplemental opioid utilization, opioid-related symptoms, and Patient/Physician Global Evaluation of Study Medication were compared between placebo and parecoxib groups in the 2−3 days following surgery. RESULTS: Significantly (p<0.001) lower pain scores were observed in the parecoxib group (n=111), relative to placebo (n=126), on Day 2 (−33%) and Day 3 (−35%). Pain interference with function scores was also significantly (p<0.001) lower among patients receiving parecoxib compared with placebo on Day 2 (−29%) and Day 3 (−36%). At 24, 48, and 72 hours, the cumulative amount of supplemental morphine consumed was 45%, 41%, and 40% less in patients receiving parecoxib compared with placebo (all p<0.001). The risk of experiencing ≥1 opioid-related symptoms was also significantly lower with parecoxib than with placebo on Day 2 (relative risk=0.75; p<0.001). Specifically, the risks of fatigue and drowsiness were significantly (both p<0.05) lower in patients receiving parecoxib compared to those receiving placebo. Patient and Physician Global Evaluation of Study Medication scores were significantly better in the parecoxib group than in the placebo group (p<0.001). CONCLUSION: This study is the first to demonstrate that multiple-dose parecoxib, initiated upon recovery from anesthesia, provides analgesia and opioid-sparing effects following a variety of major gastrointestinal surgeries employing laparotomy.
format Online
Article
Text
id pubmed-5627739
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-56277392017-10-12 Parecoxib relieves pain and has an opioid-sparing effect following major gastrointestinal surgery Essex, Margaret Noyes Xu, Hao Parsons, Bruce Xie, Li Li, Chunming Int J Gen Med Original Research PURPOSE: Parecoxib provides analgesia following a variety of surgeries, including minor gastrointestinal procedures. To our knowledge, there is no data on parecoxib following major gastrointestinal surgery. This study assessed the efficacy and opioid-sparing effects of parecoxib following major gastrointestinal surgeries. PATIENTS AND METHODS: Patients in this analysis were a subset from a large, randomized, double-blind, placebo-controlled trial of parecoxib following noncardiac surgeries and consisted of those undergoing a variety of major gastrointestinal surgeries via laparotomy. Pain, pain interference with function, supplemental opioid utilization, opioid-related symptoms, and Patient/Physician Global Evaluation of Study Medication were compared between placebo and parecoxib groups in the 2−3 days following surgery. RESULTS: Significantly (p<0.001) lower pain scores were observed in the parecoxib group (n=111), relative to placebo (n=126), on Day 2 (−33%) and Day 3 (−35%). Pain interference with function scores was also significantly (p<0.001) lower among patients receiving parecoxib compared with placebo on Day 2 (−29%) and Day 3 (−36%). At 24, 48, and 72 hours, the cumulative amount of supplemental morphine consumed was 45%, 41%, and 40% less in patients receiving parecoxib compared with placebo (all p<0.001). The risk of experiencing ≥1 opioid-related symptoms was also significantly lower with parecoxib than with placebo on Day 2 (relative risk=0.75; p<0.001). Specifically, the risks of fatigue and drowsiness were significantly (both p<0.05) lower in patients receiving parecoxib compared to those receiving placebo. Patient and Physician Global Evaluation of Study Medication scores were significantly better in the parecoxib group than in the placebo group (p<0.001). CONCLUSION: This study is the first to demonstrate that multiple-dose parecoxib, initiated upon recovery from anesthesia, provides analgesia and opioid-sparing effects following a variety of major gastrointestinal surgeries employing laparotomy. Dove Medical Press 2017-09-28 /pmc/articles/PMC5627739/ /pubmed/29026330 http://dx.doi.org/10.2147/IJGM.S143837 Text en © 2017 Essex et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Essex, Margaret Noyes
Xu, Hao
Parsons, Bruce
Xie, Li
Li, Chunming
Parecoxib relieves pain and has an opioid-sparing effect following major gastrointestinal surgery
title Parecoxib relieves pain and has an opioid-sparing effect following major gastrointestinal surgery
title_full Parecoxib relieves pain and has an opioid-sparing effect following major gastrointestinal surgery
title_fullStr Parecoxib relieves pain and has an opioid-sparing effect following major gastrointestinal surgery
title_full_unstemmed Parecoxib relieves pain and has an opioid-sparing effect following major gastrointestinal surgery
title_short Parecoxib relieves pain and has an opioid-sparing effect following major gastrointestinal surgery
title_sort parecoxib relieves pain and has an opioid-sparing effect following major gastrointestinal surgery
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627739/
https://www.ncbi.nlm.nih.gov/pubmed/29026330
http://dx.doi.org/10.2147/IJGM.S143837
work_keys_str_mv AT essexmargaretnoyes parecoxibrelievespainandhasanopioidsparingeffectfollowingmajorgastrointestinalsurgery
AT xuhao parecoxibrelievespainandhasanopioidsparingeffectfollowingmajorgastrointestinalsurgery
AT parsonsbruce parecoxibrelievespainandhasanopioidsparingeffectfollowingmajorgastrointestinalsurgery
AT xieli parecoxibrelievespainandhasanopioidsparingeffectfollowingmajorgastrointestinalsurgery
AT lichunming parecoxibrelievespainandhasanopioidsparingeffectfollowingmajorgastrointestinalsurgery